Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease

Abstract Background The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F]GTP1 tau PET and subsequent longitudinal change across multiple cog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Edmond Teng, Paul T. Manser, Sandra Sanabria Bohorquez, Kristin R. Wildsmith, Karen Pickthorn, Suzanne L. Baker, Michael Ward, Geoffrey A. Kerchner, Robby M. Weimer
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Tau PET Cognition Alzheimer’s disease Prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/151ea849eff2427ead44ea9980aa2f28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:151ea849eff2427ead44ea9980aa2f28
record_format	dspace
spelling	oai:doaj.org-article:151ea849eff2427ead44ea9980aa2f282021-12-05T12:24:31ZBaseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease10.1186/s13195-021-00937-x1758-9193https://doaj.org/article/151ea849eff2427ead44ea9980aa2f282021-12-01T00:00:00Zhttps://doi.org/10.1186/s13195-021-00937-xhttps://doaj.org/toc/1758-9193Abstract Background The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F]GTP1 tau PET and subsequent longitudinal change across multiple cognitive measures over 18 months. Methods Our analyses incorporated data from 67 participants, including cognitively normal controls (n = 10) and β-amyloid (Aβ)-positive individuals ([18F] florbetapir Aβ PET) with prodromal (n = 26), mild (n = 16), or moderate (n = 15) AD. Baseline measurements included cortical volume (MRI), tau burden ([18F]GTP1 tau PET), and cognitive assessments [Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), 13-item version of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)]. Cognitive assessments were repeated at 6-month intervals over an 18-month period. Associations between baseline [18F]GTP1 tau PET indices and longitudinal cognitive performance were assessed via univariate (Spearman correlations) and multivariate (linear mixed effects models) approaches. The utility of potential prognostic tau PET cut points was assessed with ROC curves. Results Univariate analyses indicated that greater baseline [18F]GTP1 tau PET signal was associated with faster rates of subsequent decline on the MMSE, CDR, and ADAS-Cog13 across regions of interest (ROIs). In multivariate analyses adjusted for baseline age, cognitive performance, cortical volume, and Aβ PET SUVR, the prognostic performance of [18F]GTP1 SUVR was most robust in the whole cortical gray ROI. When AD participants were dichotomized into low versus high tau subgroups based on baseline [18F]GTP1 PET standardized uptake value ratios (SUVR) in the temporal (cutoff = 1.325) or whole cortical gray (cutoff = 1.245) ROIs, high tau subgroups demonstrated significantly more decline on the MMSE, CDR, and ADAS-Cog13. Conclusions Our results suggest that [18F]GTP1 tau PET represents a prognostic biomarker in AD and are consistent with data from other tau PET tracers. Tau PET imaging may have utility for identifying AD patients at risk for more rapid cognitive decline and for stratification and/or enrichment of participant selection in AD clinical trials. Trial registration ClinicalTrials.gov NCT02640092 . Registered on December 28, 2015Edmond TengPaul T. ManserSandra Sanabria BohorquezKristin R. WildsmithKaren PickthornSuzanne L. BakerMichael WardGeoffrey A. KerchnerRobby M. WeimerBMCarticleTauPETCognitionAlzheimer’s diseasePrognosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENAlzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tau PET Cognition Alzheimer’s disease Prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Tau PET Cognition Alzheimer’s disease Prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Edmond Teng Paul T. Manser Sandra Sanabria Bohorquez Kristin R. Wildsmith Karen Pickthorn Suzanne L. Baker Michael Ward Geoffrey A. Kerchner Robby M. Weimer Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
description	Abstract Background The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18F]GTP1 tau PET and subsequent longitudinal change across multiple cognitive measures over 18 months. Methods Our analyses incorporated data from 67 participants, including cognitively normal controls (n = 10) and β-amyloid (Aβ)-positive individuals ([18F] florbetapir Aβ PET) with prodromal (n = 26), mild (n = 16), or moderate (n = 15) AD. Baseline measurements included cortical volume (MRI), tau burden ([18F]GTP1 tau PET), and cognitive assessments [Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), 13-item version of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)]. Cognitive assessments were repeated at 6-month intervals over an 18-month period. Associations between baseline [18F]GTP1 tau PET indices and longitudinal cognitive performance were assessed via univariate (Spearman correlations) and multivariate (linear mixed effects models) approaches. The utility of potential prognostic tau PET cut points was assessed with ROC curves. Results Univariate analyses indicated that greater baseline [18F]GTP1 tau PET signal was associated with faster rates of subsequent decline on the MMSE, CDR, and ADAS-Cog13 across regions of interest (ROIs). In multivariate analyses adjusted for baseline age, cognitive performance, cortical volume, and Aβ PET SUVR, the prognostic performance of [18F]GTP1 SUVR was most robust in the whole cortical gray ROI. When AD participants were dichotomized into low versus high tau subgroups based on baseline [18F]GTP1 PET standardized uptake value ratios (SUVR) in the temporal (cutoff = 1.325) or whole cortical gray (cutoff = 1.245) ROIs, high tau subgroups demonstrated significantly more decline on the MMSE, CDR, and ADAS-Cog13. Conclusions Our results suggest that [18F]GTP1 tau PET represents a prognostic biomarker in AD and are consistent with data from other tau PET tracers. Tau PET imaging may have utility for identifying AD patients at risk for more rapid cognitive decline and for stratification and/or enrichment of participant selection in AD clinical trials. Trial registration ClinicalTrials.gov NCT02640092 . Registered on December 28, 2015
format	article
author	Edmond Teng Paul T. Manser Sandra Sanabria Bohorquez Kristin R. Wildsmith Karen Pickthorn Suzanne L. Baker Michael Ward Geoffrey A. Kerchner Robby M. Weimer
author_facet	Edmond Teng Paul T. Manser Sandra Sanabria Bohorquez Kristin R. Wildsmith Karen Pickthorn Suzanne L. Baker Michael Ward Geoffrey A. Kerchner Robby M. Weimer
author_sort	Edmond Teng
title	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
title_short	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
title_full	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
title_fullStr	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
title_full_unstemmed	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
title_sort	baseline [18f]gtp1 tau pet imaging is associated with subsequent cognitive decline in alzheimer’s disease
publisher	BMC
publishDate	2021
url	https://doaj.org/article/151ea849eff2427ead44ea9980aa2f28
work_keys_str_mv	AT edmondteng baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT paultmanser baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT sandrasanabriabohorquez baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT kristinrwildsmith baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT karenpickthorn baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT suzannelbaker baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT michaelward baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT geoffreyakerchner baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease AT robbymweimer baseline18fgtp1taupetimagingisassociatedwithsubsequentcognitivedeclineinalzheimersdisease
_version_	1718371942972522496

Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease

Ejemplares similares